艾比森(300389.SZ)披露合夥人計劃(草案) 擬籌資總額不超2800萬元
格隆匯1月20日丨艾比森(300389.SZ)披露合夥人計劃(草案),本合夥人計劃擬籌集資金總額為不超過人民幣2800萬元,以“份”作為認購單位,每份份額為1元,合夥人計劃的總份數為不超過2800萬份。參與對象的最終人數、名單以及認購份額以員工實際繳款情況為準。
合夥人計劃的股票來源為公司回購專用賬户內已回購的股份。
擬參與本合夥人計劃的員工總人數不超過168人,具體參與人數將根據員工實際繳款情況確定,參與對象需經董事會確認、監事會核實。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.